Histrelin - Misplaced Pages

Chemical compound

This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Histrelin" – news · newspapers · books · scholar · JSTOR (September 2024)

Pharmaceutical compound

Histrelin
Clinical data

Trade names	Vantas, Supprelin LA, others
Other names	ORF-17070, RWJ-17070
AHFS/Drugs.com	Monograph
MedlinePlus	a601146
License data	US DailyMed: Histrelin
Routes of administration	Subcutaneous implant
Drug class	GnRH analogue; GnRH agonist; Antigonadotropin
ATC code	L02AE05 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	92%
Protein binding	70%
Metabolism	Liver
Elimination half-life	4.0 hours
Identifiers
IUPAC name 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-N-(diaminomethylene)-L-ornithyl-N-ethyl-L-prolinamide
CAS Number	76712-82-8 as salt: 220810-26-4
PubChem CID	25077993 as salt: 56927879
IUPHAR/BPS	3884
DrugBank	DB06788 as salt: DBSALT001172
ChemSpider	10482012 as salt: 26606349
UNII	H50H3S3W74 as salt: QMG7HLD1ZE
KEGG	D02369
ChEBI	CHEBI:5739 as salt: CHEBI:63530
ChEMBL	ChEMBL1201255 as salt: ChEMBL1200509
CompTox Dashboard (EPA)	DTXSID50227543
ECHA InfoCard	100.163.860
Chemical and physical data
Formula	C₆₆H₈₆N₁₈O₁₂
Molar mass	1323.528 g·mol
3D model (JSmol)	Interactive image as salt: Interactive image
SMILES CCNC(=O)1CCCN1C(=O)(CCCNC(=N)N)NC(=O)(CC(C)C)NC(=O)(Cc2cn(Cc3ccccc3)cn2)NC(=O)(Cc4ccc(cc4)O)NC(=O)(CO)NC(=O)(Cc5cc6ccccc56)NC(=O)(Cc7ccn7)NC(=O)8CCC(=O)N8 as salt: CCNC(=O)1CCCN1C(=O)(CCCNC(=N)N)NC(=O)(CC(C)C)NC(=O)(Cc2cn(Cc3ccccc3)cn2)NC(=O)(Cc4ccc(cc4)O)NC(=O)(CO)NC(=O)(Cc5cc6ccccc56)NC(=O)(Cc7ccn7)NC(=O)8CCC(=O)N8.CC(=O)O.CC(=O)O
InChI InChI=1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1 Key:HHXHVIJIIXKSOE-QILQGKCVSA-N as salt: InChI=1S/C66H86N18O12.2C2H4O2/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47;21-2(3)4/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71);21H3,(H,3,4)/t47-,48-,49-,50-,51-,52-,53+,54-,55-;;/m0../s1 Key:BKEMVGVBBDMHKL-VYFXDUNUSA-N
(what is this?) (verify)

Histrelin acetate, sold under the brand name Supprelin among others, is a nonapeptide analogue of gonadotropin-releasing hormone (GnRH) with added potency. When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

Medical uses

Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition, histrelin has been proven to be highly effective in treating central precocious puberty in children.

It is available as a daily intramuscular injection.

Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer, since 2005 in the US, and since January 2010 in the UK.

A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved in May 2007, by the US Food and Drug Administration.

Histrelin can be part of the primary care protocol in transgender children/youth, which is an off-label use in the USA and the UK, and is used in suppressing cis-sex puberty, until the patient is ready to begin cross-sex hormonal therapy. It is also sometimes prescribed to transgender adults who benefit from having their sex hormone production halted. In this application, patients often keep the implant for two years before replacing, with regular blood tests to monitor the hormone levels. Implants left too long are more difficult to replace.

Side effects

Common side effects include headache, hot flashes, constipation, reduced libido, gynecomastia, insomnia, renal impairment, weight loss, testicular atrophy, and erectile dysfunction.

Pharmacology

In a process known as downregulation, daily stimulation of pituitary gonadotropes causes them to become desensitized to the effects of histrelin. As a consequence, levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fall after a short period of time. From that point forward, as long as histrelin is administered, the levels of LH and FSH in the blood remain low.

This prolonged lowering of LH and FSH levels is the rationale for therapy using GnRH agonists. Since LH and FSH stimulate the gonads to produce estrogens and androgens in females and males respectively, histrelin can effectively be used to decrease the sex steroids in the blood of patients.

Society and culture

Since 2020, Vantas is not available anymore. Endo, its manufacturer said batches of the medication were not coming out right. They added that although Supprelin and Vantas were manufactured in the same facility, they were not identical product (though both contain 50 mg of histrelin acetate.) As of 2023, Vantas is still not available and the only available implant is Supprelin LA.

Economics

Vantas was priced around $4400 in 2004 while Supprelin LA was priced at $37,000 in 2007.

References

"Supprelin LA- histrelin acetate implant". DailyMed. 30 April 2022. Retrieved 25 September 2024.
Davis M (25 February 2005). Chandramouli J (ed.). "Histrelin acetate (Vantas)". New Drug Bulletins. University of Utah Hospitals & Clinics. Archived from the original on 10 May 2006.
"Histrelin consumer information". Drugs.com.
Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. (May 2007). "Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial". The Journal of Clinical Endocrinology and Metabolism. 92 (5): 1697–1704. doi:10.1210/jc.2006-2479. PMID 17327379.{{cite journal}}: CS1 maint: overridden setting (link)
"Primary Care Protocol for Transgender Patient Care: Hormone Administration". Center of Excellence for Transgender Health. University of California, San Francisco, Department of Family and Community Medicine. April 2011. Archived from the original on 17 January 2012. Retrieved 29 September 2015.
Cohen D, Barnes H (September 2019). "Gender dysphoria in children: puberty blockers study draws further criticism". BMJ. 366: l5647. doi:10.1136/bmj.l5647. PMID 31540909. S2CID 202711942.
Marinkovic M, Carswell J, Roberts SA (2019). "Emerging Developments in Pubertal Suppression for Gender Incongruent/Gender Dysphoric Youth". In Finlayson C (ed.). Pubertal Suppression in Transgender Youth. pp. 95–100. doi:10.1016/B978-0-323-56963-7.00012-0. ISBN 978-0-323-56963-7. S2CID 186736821.
Drugs.com: Histrelin Monograph
Mutschler E, Schäfer-Korting M (2001). Arzneimittelwirkungen (in German) (8th ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 372–3. ISBN 3-8047-1763-2.
Wuttke W, Jarry H, Feleder C, Moguilevsky J, Leonhardt S, Seong JY, et al. (1996). "The neurochemistry of the GnRH pulse generator". Acta Neurobiologiae Experimentalis. 56 (3): 707–713. doi:10.55782/ane-1996-1176. PMID 8917899. Archived from the original on 8 December 2015. Retrieved 27 November 2015.
Lupkin S (6 November 2021). "Drugmaker drops cheaper version of drug, leaving patients stuck with pricier one". National Public Radio (NPR).
Lupkin S (24 February 2020). "Hormone Blocker Sticker Shock: Kids Drug Costs 8 Times More Than One For Adults". National Public Radio (NPR).